Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? - Wikidata - wikimedia - TriplyDB

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

http://www.wikidata.org/entity/Q38184380

about

Molecular mechanisms of peritoneal dissemination in gastric cancer Gastric biomarkers: a global review Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis Recent advances in the molecular diagnostics of gastric cancer Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers Gastric cancer review A CD44-specific peptide, RP-1, exhibits capacities of assisting diagnosis and predicting prognosis of gastric cancer.RETRACTED: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients The role of gastrokine 1 in gastric cancer.Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer.Causes and consequences of microsatellite instability in gastric carcinogenesis.The Influence of PSCA Gene Variation on Its Expression and Gastric Adenocarcinoma Susceptibility in the Northwest Chinese Population.LncRNA-AP001631.9 promotes cell migration in gastric cancer.Upregulated long intergenic noncoding RNA KRT18P55 acts as a novel biomarker for the progression of intestinal-type gastric cancer.Decreased miR-198 expression and its prognostic significance in human gastric cancer Correlation between FOXP3 expression and gastric cancer.Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer miRNA-558 promotes gastric cancer progression through attenuating Smad4-mediated repression of heparanase expression.miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14.Targeted therapy in gastric cancer.Updated evidence on adjuvant treatments for gastric cancer.miRNA-584-3p inhibits gastric cancer progression by repressing Yin Yang 1- facilitated MMP-14 expression Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.Decreased expression of hsa_circ_0001895 in human gastric cancer and its clinical significances.PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.Function and diagnostic value of Anosmin-1 in gastric cancer progression.The novel long noncoding RNA AC138128.1 may be a predictive biomarker in gastric cancer.Low expression of lncRNA-HMlincRNA717 in human gastric cancer and its clinical significances.Predictive biomarkers along gastric cancer pathogenetic pathways.Overexpression of long noncoding RNA HOTTIP promotes tumor invasion and predicts poor prognosis in gastric cancer.Clinical significance of the low expression of FER1L4 in gastric cancer patients.High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy.Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer.SLC3A2, antigen of mAb 3G9, promotes migration and invasion by upregulating of mucins in gastric cancer.Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin β1-FAK signaling pathway.Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer.Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies.Long non-coding RNA DLEU1 predicts poor prognosis of gastric cancer and contributes to cell proliferation by epigenetically suppressing KLF2.Development of Novel Monoclonal Antibodies for Evaluation of Transmembrane Prostate Androgen-Induced Protein 1 (TMEPAI) Expression Patterns in Gastric Cancer.

P2860

Q26738538-4FB128FF-E644-4B36-BEA4-6466399186E5 Q26741859-C09CE303-4179-4E4F-BB0D-0A94044AD7DF Q26769034-BECBA452-F822-42FB-94C2-9733C15850F3 Q26785548-3EACC5F4-8745-4228-B52E-10D40D8412D5 Q26801289-A7CC4A49-9311-4993-868B-DE5745E4518C Q27025793-C03630C1-DF22-4EC0-9357-E29F559E8C61 Q33728237-5027EA25-05A5-4FFE-A9A6-7DBA9A958DEE Q34252182-9585E5B7-1B29-4C1C-B0BC-BD77A44DBE30 Q34353195-157CF89A-5ABD-4A79-8C04-24CC650D939B Q34501774-7B1F3595-9338-44E8-A3C1-781B4CA549B3 Q34565529-98408393-A63E-47F7-8885-CD1C672E8B9B Q34589660-ED31FABF-24FD-4DD3-9804-949F9A0275D3 Q35723916-7D4E70B0-FADE-47B7-9EEC-A02D3D14C3DC Q35918935-5916F17C-E8F7-4528-9BEA-06C823125CC2 Q36504164-8C206746-C270-4798-949A-21819E338081 Q36553216-0B704D04-1119-42C9-8700-A8912DF14244 Q37106493-74578C5A-0A3E-4187-97B3-D3798A69752B Q37216983-C0DD6BAA-F624-4700-9314-99FA8532E752 Q37330924-1635C6FF-934F-449F-92E0-9D62161CBD72 Q37457865-29699788-A047-4248-AA69-EFDE57C1FC5B Q38364292-836228EA-B25B-4231-9B68-F4D013BD8578 Q38594498-BCD7E561-F4BF-4AB6-9768-22A521C6A418 Q38615332-336128FF-8365-41B6-BE5E-9AF4E17900E4 Q38699434-79E44FC2-5C18-4581-A592-54228A08F4B2 Q38706060-ADC783D5-250F-4DF1-BC33-A3427DDFD657 Q38725920-17F027CF-913D-4D04-B2FF-59C69F39143A Q38844030-317E5C0B-6503-458E-85D3-93CBDED5031D Q38952969-B1C81500-C1E4-46B6-9306-F8900BC05590 Q38981653-5DBFA142-652A-4B80-A998-B6A5A6B3B409 Q39170872-202F9E63-EF7C-4E5B-AE5B-DF5AA693B9C9 Q40038421-BF9A7828-EE51-4DCD-9977-59FC9F5FF476 Q43653975-2D63AA06-47E6-43F6-A11B-75903C564CB8 Q43824474-CFFB6607-5E23-461A-9FF2-3B563477B4E5 Q46668930-E59B74C2-4ACC-4558-BBC1-77134175740A Q47101416-859A3D23-7CBC-4379-9919-374B0B50FEB1 Q48099844-23D4D668-0183-40E1-976D-53186A7E1280 Q48379063-EA22833E-0178-4E48-A598-34FCA8338980 Q49183232-ECC8640E-0FDA-431F-B2BA-77FA2506A287 Q49546834-4D2DD0AE-F88B-4331-BB0B-0127F417C871 Q50205607-2008FBFB-C201-49D6-BD5C-09B6643C56E3

P2860

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

http://www.wikidata.org/entity/Q38184380

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

@en

type

label

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

@en

prefLabel

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

@en

P1433

Q38184380-9E418829-DDE4-4215-8CD7-69DF7EFE8D32

P1476

Q38184380-ACEB32AA-F0B2-4EFC-9872-9E85067EFA01

P2860

Q38184380-060C08E7-7E78-4A71-80B8-99840CB04942

Q38184380-06E189A0-33D5-4172-A182-32CE40E1587C

Q38184380-0C920FBA-6DC4-4EF1-9CF4-6040263C4521

Q38184380-0FF94359-6274-454D-ABEB-CEC8A9022FC8

Q38184380-1140D117-D0C3-40E2-BFFA-7D95A10E2FDF

Q38184380-127940DA-849A-4DAC-A3EC-94E28795E648

Q38184380-211710CD-4805-4C10-AA03-701A8C0E4430

Q38184380-23D99C4D-0468-4F91-908D-39212308EF37

Q38184380-2403796C-F5F1-4284-844D-29E334591790

Q38184380-24CF6FE9-62D9-4F00-9E72-730C8947993A

P2888

Q38184380-DD35CA03-48E9-4245-9A07-A0EF393086DF

P304

Q38184380-D554A228-0417-4901-AE3B-B3E2DCAA59EE

P31

Q38184380-F183B0DA-0BE6-4198-A020-3DD63EB1B692

P356

Q38184380-8824C925-5F0D-4E57-A515-8FE41A1409BF

P433

Q38184380-E964BD4D-3EDE-433A-8A0A-EC83ABC22655

P478

Q38184380-8F46F352-592E-4F34-A6FF-32D7002B1629

P50

Q38184380-18D8261B-46B8-4194-BF3D-C04ED23789F9

Q38184380-4E8F274C-D3A4-488E-9C58-CA8A2835D7CC

Q38184380-62575EDD-5C0B-4957-9927-519F30DD1A2D

Q38184380-6D88B847-6B11-48DF-8594-142011E9682C

Q38184380-FAACC9D8-151F-411F-97C6-0CCB6D7A84C9

P577

Q38184380-7559215C-2CE7-40A0-84EB-3A7956A4AEE2

P5875

Q38184380-40BACB9B-2C2A-4495-90F0-CFEA784E4ECB

P698

Q38184380-9118ACD6-2282-4DEB-99D4-3217BABFD50A

P921

Q38184380-9E0639B0-A5E8-488D-9C48-FA8A59EA5A71

P356

S00428-013-1533-Y

P1433

Virchows Archiv

P1476

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

@en

P2860

Global cancer statistics

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

High frequency of mutations of the PIK3CA gene in human cancers

P2888

s00428-013-1533-y

P304

367-378

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00428-013-1533-Y

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

464

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela M. Almeida

Fatima Carneiro

Cecília Durães

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260040333

http://www.w3.org/2001/XMLSchema#string

P698

24487788

http://www.w3.org/2001/XMLSchema#string

P921